- Home
- GPCR vs SNDX Comparison
GPCR vs SNDX Comparison
Compare GPCR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- SNDX
- Stock Information
- Founded
- GPCR 2016
- SNDX 2005
- Country
- GPCR United States
- SNDX United States
- Employees
- GPCR N/A
- SNDX N/A
- Industry
- GPCR
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- GPCR
- SNDX Health Care
- Exchange
- GPCR Nasdaq
- SNDX Nasdaq
- Market Cap
- GPCR 1.1B
- SNDX 1.1B
- IPO Year
- GPCR 2023
- SNDX 2016
- Fundamental
- Price
- GPCR $19.01
- SNDX $9.60
- Analyst Decision
- GPCR Strong Buy
- SNDX Strong Buy
- Analyst Count
- GPCR 7
- SNDX 11
- Target Price
- GPCR $76.17
- SNDX $34.18
- AVG Volume (30 Days)
- GPCR 684.5K
- SNDX 2.0M
- Earning Date
- GPCR 08-07-2025
- SNDX 07-31-2025
- Dividend Yield
- GPCR N/A
- SNDX N/A
- EPS Growth
- GPCR N/A
- SNDX N/A
- EPS
- GPCR N/A
- SNDX N/A
- Revenue
- GPCR N/A
- SNDX $43,722,000.00
- Revenue This Year
- GPCR N/A
- SNDX $426.77
- Revenue Next Year
- GPCR N/A
- SNDX $98.31
- P/E Ratio
- GPCR N/A
- SNDX N/A
- Revenue Growth
- GPCR N/A
- SNDX N/A
- 52 Week Low
- GPCR $13.22
- SNDX $8.58
- 52 Week High
- GPCR $47.48
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- GPCR 33.96
- SNDX 48.99
- Support Level
- GPCR $18.50
- SNDX $8.59
- Resistance Level
- GPCR $19.40
- SNDX $10.01
- Average True Range (ATR)
- GPCR 1.18
- SNDX 0.54
- MACD
- GPCR -0.17
- SNDX 0.10
- Stochastic Oscillator
- GPCR 9.86
- SNDX 71.48
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.